JP2019512205A - 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 - Google Patents
癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 Download PDFInfo
- Publication number
- JP2019512205A JP2019512205A JP2018525591A JP2018525591A JP2019512205A JP 2019512205 A JP2019512205 A JP 2019512205A JP 2018525591 A JP2018525591 A JP 2018525591A JP 2018525591 A JP2018525591 A JP 2018525591A JP 2019512205 A JP2019512205 A JP 2019512205A
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- nucleic acid
- foreign nucleic
- acid sequence
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 91
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 239000013598 vector Substances 0.000 title claims abstract description 25
- 230000000174 oncolytic effect Effects 0.000 title claims description 58
- 241000700584 Simplexvirus Species 0.000 title claims description 10
- 238000011282 treatment Methods 0.000 title abstract description 23
- 238000010276 construction Methods 0.000 title description 7
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 98
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 75
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 36
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 108020005202 Viral DNA Proteins 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 100
- 239000003795 chemical substances by application Substances 0.000 claims description 76
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 32
- 108700026244 Open Reading Frames Proteins 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 26
- 238000012217 deletion Methods 0.000 claims description 25
- 230000037430 deletion Effects 0.000 claims description 25
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 24
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 23
- 108010065805 Interleukin-12 Proteins 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 8
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 101150027249 RL1 gene Proteins 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 101150073128 56 gene Proteins 0.000 claims description 7
- 101150090364 ICP0 gene Proteins 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- 101150027427 ICP4 gene Proteins 0.000 claims description 6
- 101150084750 1 gene Proteins 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 230000002601 intratumoral effect Effects 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical class C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 102000000588 Interleukin-2 Human genes 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 101000853009 Homo sapiens Interleukin-24 Proteins 0.000 claims description 2
- 102100036671 Interleukin-24 Human genes 0.000 claims description 2
- 108010066979 Interleukin-27 Proteins 0.000 claims description 2
- 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 108700005077 Viral Genes Proteins 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011477 surgical intervention Methods 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 84
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 65
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 43
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 22
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 241001212077 Iris mild mosaic virus Species 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 102000004196 processed proteins & peptides Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 102000053602 DNA Human genes 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 229920001184 polypeptide Polymers 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 13
- 241000701022 Cytomegalovirus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 244000309459 oncolytic virus Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 9
- 238000009650 gentamicin protection assay Methods 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 description 5
- 230000005975 antitumor immune response Effects 0.000 description 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 208000007569 Giant Cell Tumors Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 230000033289 adaptive immune response Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 102000043321 human CTLA4 Human genes 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- -1 domains Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 102100021253 Antileukoproteinase Human genes 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 101000770383 Bacillus subtilis (strain 168) Uncharacterized zinc protease YmxG Proteins 0.000 description 2
- 108010014064 CCCTC-Binding Factor Proteins 0.000 description 2
- 101150080924 CNE1 gene Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- 101710089751 Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 2
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102000001218 Rec A Recombinases Human genes 0.000 description 2
- 108010055016 Rec A Recombinases Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 108010082545 Secretory Leukocyte Peptidase Inhibitor Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000768 catecholaminergic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000000267 erythroid cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000048362 human PDCD1 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000007538 neurilemmoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039667 schwannoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 101150084399 37 gene Proteins 0.000 description 1
- 101150029429 38 gene Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 101150100936 CD28 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000056372 ErbB-3 Receptor Human genes 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000002090 Fibronectin type III Human genes 0.000 description 1
- 108050009401 Fibronectin type III Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000963438 Gaussia <copepod> Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 description 1
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 101150076998 ICP34.5 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102000016997 Lithostathine Human genes 0.000 description 1
- 108010014691 Lithostathine Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000844719 Mus musculus Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102100038931 Proenkephalin-A Human genes 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101000788153 Rhizobium leguminosarum bv. phaseoli Uncharacterized 11.3 kDa protein in psiA-psiB intergenic region Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 101100380504 Schizosaccharomyces pombe (strain 972 / ATCC 24843) atf1 gene Proteins 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 102000017303 Stromelysin-3 Human genes 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101150102071 TRX1 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 1
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 101150036065 UL37 gene Proteins 0.000 description 1
- 101150090946 UL38 gene Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 101150117115 V gene Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000013640 alpha-Crystallin B Chain Human genes 0.000 description 1
- 108010051585 alpha-Crystallin B Chain Proteins 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010041071 proenkephalin Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 208000012049 salivary gland mucoepidermoid carcinoma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 201000008440 thyroid gland anaplastic carcinoma Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 108090000195 villin Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000013298 xenograft nude mouse model Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本明細書における「一」又は「1つ」の実体という用語は、当該実体のうちの1つ又は複数を指す。例えば、「組み換え腫瘍溶解性HSV−1」は、1つ又は複数の組み換え腫瘍溶解性HSV−1ウイルスを表すものと理解される。よって、「1つ」、「1つ又は複数」及び「少なくとも1つ」といった用語は、本明細書で相互に置き換えて用いることができる。
本発明の一態様として、改変されたHSV−1ゲノムを含むHSV−1ウイルスを提供し、HSV−1偏性ベクターとも呼ばれる。HSV−1ゲノムは共有結合する2つの成分(LとSと称する)からなる。各成分はユニーク配列(L成分はUL、S成分はUS)からなり、両側は逆方向反復配列である。L成分の逆方向反復配列はabとb’a’と呼ばれ、S成分の逆方向反復配列はa’c’とcaと呼ばれる。逆方向反復領域には2コピーの転写単位が含まれている。本分野では、少なくとも5つの2コピーを有するオープンリーディングフレームが知られており、これらのタンパク質はそれぞれICP0、ICP4、ICP34.5、ORF P及びORF Oと名づけられる。逆方向反復配列b’a’とa’c’(b’a’−a’c’)が結合して内部逆方向反復領域を形成する。そして、逆方向反復配列abとcaは本明細書で外部反復領域と呼ばれる。
少なくとも5種のタンパク質(ICP0、ICP4、ICP34.5、ORF−O及びORF−P)をコードする転写単位の1つのコピー(ただし残りすべてのオープンリーディングフレームが保持される)(a)、
b’a’−a’c’配列内に全体で包含される転写単位(b)、及び
ユニーク領域から始まり、欠失された領域まで延伸する転写単位(c)を含む。
外来DNA配列を野生型ウイルスに挿入すると、DNAをビリオンにパッケージすることが干渉されるため、その挿入量に制限がある。所定の領域における正確な欠失により、外来DNA配列を挿入するのに好適なスペースが与えられる。本発明の一実施形態によれば、前記欠失により、腫瘍溶解性ウイルスベクターから少なくとも15Kbpが除去され、これにより相当量の外来DNA配列を受け入れることができる。また他の関連研究によると、野生型ゲノムは7KBのDNAをさらに受け入れることができる。
いくつかの実施形態では、本発明によるoHSV−1は、サイトカイン(例えばIL−2、IL4、IL−12、GM−CSF、IFNγ)、ケモカイン(例えばMIP−1、MCP−1、IL−8)及び成長因子(例えばFLT3リガンド)を含む1種又は複数種の免疫刺激剤(免疫刺激分子とも呼ばれる)をコードする。
本発明の一態様として、抗PD−1剤及び/又は抗CTLA−4剤をコードする外来核酸を含む腫瘍溶解性ウイルスを提供する。いくつかの実施形態では、抗PD−1剤又は抗CTLA−4剤には、PD−1又はCTLA−4エピトープに特異的結合する抗体可変領域が含まれている。抗体可変領域は、例えば完全抗体、抗体フラグメント及び抗体又は抗体フラグメントの組み換え誘導体に存在してもよい。「抗体」という用語は、天然、一部合成又は全体合成の免疫グロブリンを指すものである。よって、本発明の抗PD−1剤又は抗CTLA−4剤は、PD−1又はCTLA−4エピトープに特異的結合する結合ドメインを有するあらゆるポリペプチド又はタンパク質を含む。
腫瘍溶解性ウイルスは、適切な薬学的に許容可能な担体又は賦形剤の中で製造することができる。通常の保管と使用条件では、これらの製剤には微生物の成長を防止する防腐剤が含まれている。注射用に好適な投与剤型は、無菌水溶液や、分散液又は無菌注射溶液や分散液の仮調製に用いる無菌粉末(米国特許登録第5,466,468号)を含む。あらゆる場合において、製剤は無菌でなくてはならず、且つ注射を容易にするために流体としなければならない。製造と保管の条件において安定する状態を保たなければならず、且つ細菌と真菌などの微生物による汚染も防止しなければならない。
本発明のもう一つの態様は、治療を必要とする被験者に組み換え腫瘍溶解性HSV−1ウイルス又は上記組み換え腫瘍溶解性HSV−1ウイルスを含む医薬組成物の有効量の投与を含む、癌を治療又は寛解する方法を提供する。また本発明は、上記の癌を治療又は寛解する方法に用いる腫瘍溶解性HSV−1ウイルスを合わせて提供する。
細菌人工染色体(BAC)技術による偏性ベクター−IMMV201の生成において、3つの終止(STOP)コドンを生成するCMVプロモーターカセットであるATGCAGGTGCAGTAATAGTAAカセットをT−Easyベクターの中に挿入した。プロトタイプ(P)配置のHSV−1を用いられる。それぞれ2セットのプライマー(GAAGATCTAATATTTTTATTGCAACTCCCTG、CTAGCTAGCTTATAAAAGGCGCGTCCCGTGG)と(GCTCTAGATTGCGACGCCCCGGCTC、CCTTAATTAAGGTTACCACCCTGTAGCCCCGATGT)によってHSV−1ウイルスゲノムから、上流側がヌクレオチド117005に連結され、下流側がヌクレオチド132096に連結される遺伝子カセットをPCR増幅させ、上記CMVと3つの終止コドンを含むプラスミドの中に挿入し、そして当該遺伝子置き換えプラスミドをpKO5の中に構築することにより、pKO−CMV−STOPを得た。pKO−CMV−STOPを電気穿孔法によってBAC HSVを担持する大腸菌RecA +の中に導入することによりIMMV201を得た。
OptiMEM agency(Life Technologies社)を用いて説明書に従って、上記のように構築されたBAC−IMMV201の2〜3μgを70%コンフルエント状態のVero細胞の中にトランスフェクトした。37℃、5%CO2のインキュベーターの中で4時間インキュベーション。インキュベーション後、新鮮な完全成長培地(5%新生仔ウシ血清/DMEM)4mLで置換。3〜4日以内にウイルスのプラークが認められなかった。実験を3回繰り返すところ、ウイルスのプラークが認められなかった。
pKO遺伝子カセットを電気穿孔法によってIMMV201を担持する大腸菌RecA +の中に導入することにより、免疫刺激遺伝子(マウスIL12、ヒトIL12)又は免疫治療遺伝子(ヒトPD−1 scFV(配列番号1又は3)、ヒトCTLA−4 scFV(配列番号5)を駆動するCMVプロモーター遺伝子カセットを得た(図1参照)。
免疫刺激遺伝子(IL12)と免疫治療遺伝子(PD−1 scFV、CTLA−4 scFV)を駆動するCMVプロモーターカセットを、さらに、IMMV202、203、303、403ベクターにおけるUL3とUL4遺伝子の間に挿入することにより免疫刺激遺伝子(IL12)と免疫治療遺伝子の組み合わせを発現する組み換えoHSVを生成した(図2参照)。
IMMV503ベクター(図2参照)におけるUL37とUL38遺伝子の間にCTLA−4 scFVを挿入することにより、ヒトIL12、PD−1 scFVとCTLA−4 scFVをコードする3種の免疫刺激cDNA及び免疫治療cDNAを発現するIMMV603を構築した。
本明細書に記載の一連の実験では、モック又はプラスミドでトランスフェクトされる2×106個のH293T細胞は、CMVプロモーターにより駆動されHisタグscFV−抗−PD−1をコードするcDNA及び各種自然源に由来するシグナルペプチドコーディング領域を含む。トランスフェクト46時間後、細胞溶解物と上澄み液を収集し、SDS−PAGEを行って抗His抗体によってウェスタンブロッティングを行った。上澄み液2mLから40μL、細胞溶解物200μLから30μLを取り出して12%のPAGEゲルにロードした。細胞培養の上澄み液の中に蓄積されるPD−1 scFVの量(図3参照)は異なるシグナルペプチドの効率を反映している。
モック又はプラスミドでトランスフェクトされる2×106個のH293T細胞はCMVプロモーターにより駆動されHisタグscFV−抗PD−1をコードするcDNA及びHMM38シグナルペプチドを含む。トランスフェクト46時間後、上澄み液を収集し、そしてELISAアッセイを行い、抗His抗体を用いて検出した(図4参照)。分泌されたPD−1 scFVは用量依存的にPD−1と結合する。
モック(陰性対照)又はIMMV507(PD−1抗体及びCTLA−4抗体を発現するoHSV−1)を用いて、それぞれ各細胞に対する0.01、0.1、1、10、100の倍率のPFUで、96ウェルプレートに接種した5×103個の次に示すヒト腫瘍細胞を感染した。CCK−8キットを用いて、成長の細胞生存性を、96時間が経過するまで24時間ごとに測定した(図5参照)。マイクロプレートリーダー(BiotekEpoch社)を用いて450nmでの吸光度を測定した。
1. Andreansky, S., Soroceanu, L., Flotte, E. R., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B., and Whitley, R. J. (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57, 1502-1509.
2. Andreansky, S., He, B., van Cott, J., McGhee, J. V., Markert, J.M., e, Y., Roizman, B. and Whitley, R. J. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5:121-130, 1998.
3. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., Delman, K. A., Spitler, L. E., Puzanov, I., Agarwala, S. S., Milhem, M., Cranmer, L., Curti, B., Lewis, K., Ross, M., Guthrie, T., Linette, G. P., Daniels, G. A., Harrington, K., Middleton, M. R., Miller, W. H., Jr., Zager, J. S., Ye, Y., Yao, B., Li, A., Doleman, S., VanderWalde, A., Gansert, J., and Coffin, R. S. (2015). Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol.
4. Brunda, M. J. (1994). Interleukin-12. J Leukoc Biol 55, 280-288.
5. Burgess, A. W., Camakaris, J., and Metcalf, D. (1977). Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem 252, 1998-2003.
6. Cassady, K. A., Gross, M., and Roizman, B. (1998a). The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2. J Virol 72, 8620-8626.
7. Cassady, K. A., Gross, M., and Roizman, B. (1998b). The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha. J Virol 72, 7005-7011.
8. Cheema, T. A., Wakimoto, H., Fecci, P. E., Ning, J., Kuroda, T., Jeyaretna, D. S., Martuza, R. L., and Rabkin, S. D. (2013). Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A 110, 12006-12011.
9. Chou, J., Chen, J. J., Gross, M., and Roizman, B. (1995). Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1. Proc Natl Acad Sci U S A 92, 10516-10520.
10. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
11. Chou, J., and Roizman, B. (1992). The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A 89, 3266-3270.
12. Cozzi, P. J., Burke, P. B., Bhargav, A., Heston, W. D., Huryk, B., Scardino, P. T., and Fong, Y. (2002). Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses. Prostate 53, 95-100.
13. Cozzi, P. J., Malhotra, S., McAuliffe, P., Kooby, D. A., Federoff, H. J., Huryk, B., Johnson, P., Scardino, P. T., Heston, W. D., and Fong, Y. (2001). Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 15, 1306-1308.
14. Currier, M. A., Adams, L. C., Mahller, Y. Y., and Cripe, T. P. (2005). Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 12, 407-416.
15. Dharmadhikari, N., Mehnert, J. M., and Kaufman, H. L. (2015). Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol 16, 326.
16. Fife, B. T., and Pauken, K. E. (2011). The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 1217, 45-59.
17. Fong, Y., Kim, T., Bhargava, A., Schwartz, L., Brown, K., Brody, L., Covey, A., Karrasch, M., Getrajdman, G., Mescheder, A., Jarnagin, W., and Kemeny, N. (2009). A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. Mol Ther 17, 389-394.
18. Francisco, L. M., Sage, P. T., and Sharpe, A. H. (2010). The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236, 219-242.
19. Geevarghese, S. K., Geller, D. A., de Haan, H. A., Horer, M., Knoll, A. E., Mescheder, A., Nemunaitis, J., Reid, T. R., Sze, D. Y., Tanabe, K. K., and Tawfik, H. (2010). Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 21, 1119-1128.
20. Goshima, F., Esaki, S., Luo, C., Kamakura, M., Kimura, H., and Nishiyama, Y. (2014). Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer. Int J Cancer 134, 2865-2877.
21. Hsieh, C. S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., and Murphy, K. M. (1993). Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260, 547-549.
22. Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., and Steinman, R. M. (1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176, 1693-1702.
23. Keir, M. E., Butte, M. J., Freeman, G. J., and Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26, 677-704.
24. Kelly, K. J., Wong, J., and Fong, Y. (2008). Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy. Expert Opin Investig Drugs 17, 1105-1113.
25. Kemeny, N., Brown, K., Covey, A., Kim, T., Bhargava, A., Brody, L., Guilfoyle, B., Haag, N. P., Karrasch, M., Glasschroeder, B., Knoll, A., Getrajdman, G., Kowal, K. J., Jarnagin, W. R., and Fong, Y. (2006). Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17, 1214-1224.
26. Krummel, M. F., and Allison, J. P. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182, 459-465.
27. Markert, J. M., Cody, J. J., Parker, J. N., Coleman, J. M., Price, K. H., Kern, E. R., Quenelle, D. C., Lakeman, A. D., Schoeb, T. R., Palmer, C. A., Cartner, S. C., Gillespie, G. Y., and Whitley, R. J. (2012). Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol 86, 5304-5313.
28. Markert, J. M., Gillespie, G. Y., Weichselbaum, R. R., Roizman, B., and Whitley, R. J. (2000). Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10, 17-30.
29. Markowicz, S., and Engleman, E. G. (1990). Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J Clin Invest 85, 955-961.
30. Meignier, B., Longnecker, R., and Roizman, B. (1988). In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 158, 602-614.
31. Miest, T. S., and Cattaneo, R. (2014). New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol 12, 23-34.
32. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938-943.
33. Russell, S. J., Peng, K. W., and Bell, J. C. (2012). Oncolytic virotherapy. Nat Biotechnol 30, 658-670.
34. Shen, Y., and Nemunaitis, J. (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13, 975-992.
35. Smith, K. D., Mezhir, J. J., Bickenbach, K., Veerapong, J., Charron, J., Posner, M. C., Roizman, B., and Weichselbaum, R. R. (2006). Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. J Virol 80, 1110-1120.
36. Topalian, S. L., Drake, C. G., and Pardoll, D. M. (2015). Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 27, 450-461.
37. Valiante, N. M., Rengaraju, M., and Trinchieri, G. (1992). Role of the production of natural killer cell stimulatory factor (NKSF/IL-12) in the ability of B cell lines to stimulate T and NK cell proliferation. Cell Immunol 145, 187-198.
38. Walker, J. D., Sehgal, I., and Kousoulas, K. G. (2011). Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol 85, 7363-7371.
39. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., and Bluestone, J. A. (1994). CTLA-4 can function as a negative regulator of T cell activation. Immunity 1, 405-413.
40. Weichselbaum, R. R., Roizman, B., and Whitley, R. J. (2012). Treatment of tumors with genetically engineered herpes virus. In, pp. 11-27.
41. Wong, R. J., Kim, S. H., Joe, J. K., Shah, J. P., Johnson, P. A., and Fong, Y. (2001). Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 193, 12-21.
Claims (32)
- 改変された単純ヘルペスウイルスI型(HSV−1)であって、
野生型HSV−1ゲノムにおけるUL56遺伝子のプロモーターからUS1遺伝子のプロモーターの間の配列を欠失させることにより、(i)すべての2コピー遺伝子における1つのコピーが存在せず、なお且つ(ii)前記欠失後のウイルスDNAに存在するすべてのオープンリーディングフレーム(ORF)を発現するために必要な配列が完全であることを含む改変されたHSV−1ゲノムを含み、細胞性遺伝子又はウイルス性遺伝子のベクターとして作用することができることを特徴とする改変された単純ヘルペスウイルスI型(HSV−1)。 - 前記2コピー遺伝子は、ICP0、ICP4、ICP34.5、ORF P及びORF Oをコードする遺伝子及び欠失された領域を占める重複するノンコーディング配列を含むことを特徴とする請求項1に記載の改変されたHSV−1。
- 前記HSV−1は、プロトタイプ(P)のゲノム異性体を備えることを特徴とする請求項1に記載の改変されたHSV−1。
- 前記HSV−1は、Fウイルス株、KOSウイルス株及び17ウイルス株を含む既存のあらゆるHSVウイルス株から選択されることを特徴とする請求項1に記載の改変されたHSV−1。
- 前記欠失により、Fウイルス株ゲノムにおけるヌクレオチド位置117005から132096が除去されることを特徴とする請求項3に記載の改変されたHSV−1。
- 組み換え腫瘍溶解性単純ヘルペスウイルスI型(HSV−1)であって、
野生型HSV−1ゲノムにおけるUL56遺伝子のプロモーターからUS1遺伝子のプロモーターの間の配列を欠失させることにより、(i)すべての2コピー遺伝子における1つのコピーが存在せず、なお且つ(ii)前記欠失後のウイルスDNAに存在するすべてのオープンリーディングフレーム(ORF)を発現するために必要な配列が完全であることを含む改変されたHSV−1ゲノムと、
少なくとも前記改変されたHSV−1ゲノムの欠失された領域に安定的に導入され、免疫刺激剤及び/又は免疫治療剤をコードする外来核酸配列、とを含むことを特徴とする組み換え腫瘍溶解性単純ヘルペスウイルスI型(HSV−1)。 - 前記免疫刺激剤はGM−CSF、IL 2、IL 5、IL 12、IL 15、IL 24及びIL 27から選択されることを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 前記免疫治療剤は抗PD−1剤及び抗CTLA−4剤から選択されることを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- IL−12をコードする外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 抗PD−1剤をコードする外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 抗CTLA−4剤をコードする外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- IL−12をコードする第1の外来核酸配列及び抗PD−1剤をコードする第2の外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- IL−12をコードする第1の外来核酸配列及び抗CTLA−4剤をコードする第2の外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 抗PD−1剤をコードする第1の外来核酸配列及び抗CTLA−4剤をコードする第2の外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- IL−12をコードする第1の外来核酸配列、抗PD−1剤をコードする第2の外来核酸配列及び抗CTLA−4剤をコードする第3の外来核酸配列を含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 前記外来核酸配列に作動可能に連結されるプロモーター配列をさらに含むことを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 前記第1の外来核酸配列が前記改変されたHSV−1ゲノムの欠失された領域に挿入されており、且つ前記第2の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL3とUL4遺伝子の間に挿入されていることを特徴とする請求項12に記載の組み換え腫瘍溶解性HSV−1。
- 前記第1の外来核酸配列が前記改変されたHSV−1ゲノムの欠失された領域に挿入されており、且つ前記第2の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL3とUL4遺伝子の間に挿入されていることを特徴とする請求項13に記載の組み換え腫瘍溶解性HSV−1。
- 前記第1の外来核酸配列が前記改変されたHSV−1ゲノムの欠失された領域に挿入されており、且つ前記第2の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL3とUL4遺伝子の間に挿入されていることを特徴とする請求項14に記載の組み換え腫瘍溶解性HSV−1。
- 前記第1の外来核酸配列が前記改変されたHSV−1ゲノムの欠失された領域に挿入されており、前記第2の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL3とUL4遺伝子の間に挿入されており、且つ第3の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL37とUL38遺伝子の間に挿入されていることを特徴とする請求項15に記載の組み換え腫瘍溶解性HSV−1。
- 前記第1の外来核酸配列が前記改変されたHSV−1ゲノムの欠失された領域に挿入されており、前記第2の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL37とUL38の間に挿入されており、且つ第3の外来核酸配列が前記改変されたHSV−1ゲノムにおけるUL成分のUL3とUL4遺伝子の間に挿入されていることを特徴とする請求項15に記載の組み換え腫瘍溶解性HSV−1。
- 前記プロモーター配列はCMVプロモーター又はEgrプロモーターであることを特徴とする請求項16に記載の組み換え腫瘍溶解性HSV−1。
- 前記免疫刺激剤及び/又は免疫治療剤はヒト化されていることを特徴とする請求項6に記載の組み換え腫瘍溶解性HSV−1。
- 前記抗PD−1剤又は前記抗CTLA−4剤は、それぞれPD−1又はCTLA−4エピトープに特異的結合するための抗体可変領域を含むことを特徴とする請求項8に記載の組み換え腫瘍溶解性HSV−1。
- 前記抗体可変領域は、完全抗体、抗体フラグメント、又は前記抗体もしくは抗体フラグメントの組み換え誘導体であることを特徴とする請求項24に記載の組み換え腫瘍溶解性HSV−1。
- 医薬組成物であって、
有効量の請求項6〜25のいずれか一項に記載の組み換え腫瘍溶解性HSV−1及び薬学的に許容可能な担体を含むことを特徴とする医薬組成物。 - 前記組成物は腫瘍内投与用として調製されることを特徴とする請求項26に記載の医薬組成物。
- 癌を治療又は寛解するための方法であって、
治療を必要とする対象に対する請求項26又は27に記載の医薬組成物の有効量の投与を含むことを特徴とする癌を治療又は寛解するための方法。 - 前記医薬組成物の投与前、投与中、投与後に第2の療法を実施することを特徴とする請求項28に記載の方法。
- 前記第2の療法は、化学療法、放射的療法、免疫療法又は手術的介入から選択されることを特徴とする請求項29に記載の方法。
- 前記対象はヒトであることを特徴とする請求項28に記載の方法。
- 前記癌は、食道癌、肺癌、前立腺癌及び膀胱癌から選択されることを特徴とする請求項28に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2016/080025 WO2017181420A1 (en) | 2016-04-22 | 2016-04-22 | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020195623A Division JP7235334B2 (ja) | 2020-11-26 | 2020-11-26 | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019512205A true JP2019512205A (ja) | 2019-05-16 |
JP6802275B2 JP6802275B2 (ja) | 2020-12-16 |
Family
ID=60115496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018525591A Active JP6802275B2 (ja) | 2016-04-22 | 2016-04-22 | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 |
Country Status (12)
Country | Link |
---|---|
US (2) | US10821140B2 (ja) |
EP (1) | EP3380621A4 (ja) |
JP (1) | JP6802275B2 (ja) |
KR (2) | KR102211838B1 (ja) |
CN (2) | CN108350468B (ja) |
AU (2) | AU2016403583B2 (ja) |
CA (1) | CA3021588A1 (ja) |
HK (1) | HK1251017A1 (ja) |
IL (1) | IL262385B2 (ja) |
NZ (1) | NZ746916A (ja) |
RU (1) | RU2751236C2 (ja) |
WO (1) | WO2017181420A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020503871A (ja) * | 2017-01-09 | 2020-02-06 | レプリミュン リミテッド | 改変ウイルス |
JP2022539779A (ja) * | 2019-07-04 | 2022-09-13 | イムヴィラ・カンパニー・リミテッド | 腫瘍を治療するための医薬組成物、キット及び方法 |
JP2022544327A (ja) * | 2019-08-16 | 2022-10-17 | イムヴィラ・カンパニー・リミテッド | 全身投与のための腫瘍溶解性単純ヘルペスウイルスを含む医薬組成物 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3010987A1 (en) | 2016-01-08 | 2017-07-13 | Replimune Limited | Oncolytic herpes simplex virus type 1 strain |
RU2749050C2 (ru) | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
EP3658165A4 (en) | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | ONCOLYTIC VIRUS VECTORS AND USES THEREOF |
CN111164100B (zh) | 2017-08-03 | 2024-03-12 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | KRas G12Cの阻害剤及びそれを使用する方法 |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
CN109161562A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法 |
CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
EP3837355A4 (en) * | 2018-08-16 | 2022-07-06 | Immvira Co., Limited | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS AND MICROBIAL INFECTION |
TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
CN113227384B (zh) * | 2018-12-26 | 2023-06-06 | 深圳市亦诺微医药科技有限公司 | 用于治疗肿瘤的药物组合物、药盒和方法 |
MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
CN113439123A (zh) * | 2019-03-05 | 2021-09-24 | 安进公司 | 溶瘤病毒用于治疗癌症的用途 |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
KR20210151002A (ko) * | 2020-06-03 | 2021-12-13 | 주식회사 젠셀메드 | HveC의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도 |
JP7235334B2 (ja) * | 2020-11-26 | 2023-03-08 | イムヴィラ・カンパニー・リミテッド | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 |
TW202223085A (zh) * | 2020-12-04 | 2022-06-16 | 大陸商深圳市亦諾微醫藥科技有限公司 | 用於腦腫瘤治療的溶瘤性i型單純皰疹病毒 |
CN116656629A (zh) * | 2020-12-04 | 2023-08-29 | 深圳市亦诺微医药科技有限公司 | 用于脑肿瘤治疗的溶瘤性i型单纯疱疹病毒 |
BR112023023087A2 (pt) * | 2021-05-04 | 2024-01-30 | Alivid Llc | Uma entidade biológica para o tratamento do câncer cerebral |
WO2023226942A1 (zh) * | 2022-05-23 | 2023-11-30 | 上海药明康德新药开发有限公司 | 一种编码免疫刺激因子和抗免疫检查点抗体的重组hsv-1载体 |
WO2024067540A1 (en) * | 2022-09-30 | 2024-04-04 | Immvira Biopharmaceuticals Co., Limited | Genetically engineered herpes simplex virus type 1 for treatment of hematologic cancers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536347A (ja) * | 1999-02-05 | 2002-10-29 | アーチ デベロップメント コーポレイション | 遺伝子操作されたヘルペスウイルスを用いた腫瘍の処置 |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
WO2015066042A1 (en) * | 2013-10-28 | 2015-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic hsv vector |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8918616D0 (en) * | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
GB9415320D0 (en) * | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
GB9415319D0 (en) * | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
US5851826A (en) * | 1995-07-26 | 1998-12-22 | Children's Medical Center Corporation | Helper virus-free herpesvirus vector packaging system |
GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
US6774119B1 (en) * | 1999-04-26 | 2004-08-10 | Cedars-Sinai Medical Center | Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
US6566380B2 (en) * | 2000-07-25 | 2003-05-20 | Icagen, Inc. | Potassium channel inhibitors |
US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
WO2007132169A1 (en) * | 2006-05-11 | 2007-11-22 | Crusade Laboratories Limited | Mutant hsv, materials and methods for generation of mutant hsv |
WO2008083174A2 (en) * | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
CN101376892B (zh) * | 2007-08-28 | 2011-07-13 | 李小鹏 | 单纯疱疹病毒载体和重组病毒及宿主细胞及其药物组合物 |
US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
WO2013180967A1 (en) * | 2012-05-29 | 2013-12-05 | Genvec, Inc. | Herpes simplex virus vaccine |
CA2918535A1 (en) * | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
CN103589754A (zh) * | 2013-10-24 | 2014-02-19 | 新疆大学 | 一种1型单纯疱疹病毒载体系统及其制备方法与应用 |
MX2018005467A (es) * | 2015-11-09 | 2018-12-11 | Immune Design Corp | Composiciones que comprenden vectores lentivirales que expresan interleucina-12, y metodos de uso de las mismas. |
CA3010987A1 (en) * | 2016-01-08 | 2017-07-13 | Replimune Limited | Oncolytic herpes simplex virus type 1 strain |
-
2016
- 2016-04-22 EP EP16899007.5A patent/EP3380621A4/en active Pending
- 2016-04-22 NZ NZ746916A patent/NZ746916A/en unknown
- 2016-04-22 CN CN201680065759.5A patent/CN108350468B/zh active Active
- 2016-04-22 JP JP2018525591A patent/JP6802275B2/ja active Active
- 2016-04-22 CN CN202011050904.7A patent/CN112575036A/zh active Pending
- 2016-04-22 US US16/077,417 patent/US10821140B2/en active Active
- 2016-04-22 RU RU2018136481A patent/RU2751236C2/ru active
- 2016-04-22 IL IL262385A patent/IL262385B2/en unknown
- 2016-04-22 CA CA3021588A patent/CA3021588A1/en active Pending
- 2016-04-22 KR KR1020187021388A patent/KR102211838B1/ko active IP Right Grant
- 2016-04-22 KR KR1020217002912A patent/KR102323872B1/ko active IP Right Grant
- 2016-04-22 AU AU2016403583A patent/AU2016403583B2/en active Active
- 2016-04-22 WO PCT/CN2016/080025 patent/WO2017181420A1/en active Application Filing
-
2018
- 2018-08-15 HK HK18110470.8A patent/HK1251017A1/zh unknown
-
2020
- 2020-06-24 AU AU2020204209A patent/AU2020204209B2/en active Active
- 2020-09-14 US US17/020,666 patent/US11439679B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536347A (ja) * | 1999-02-05 | 2002-10-29 | アーチ デベロップメント コーポレイション | 遺伝子操作されたヘルペスウイルスを用いた腫瘍の処置 |
WO2014047350A1 (en) * | 2012-09-20 | 2014-03-27 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
WO2015066042A1 (en) * | 2013-10-28 | 2015-05-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic hsv vector |
Non-Patent Citations (1)
Title |
---|
"Khalique H., "Transcriptional control of ICPO and its effect on herpes simplex virus-1 replication"", A DOCTOR THESIS SUBMITTED THE AUTONOMOUS UNIVERSITY OF MADRID [ONLINE], UPLOADED ON 2015.06.18, PP., JPN6020005095, ISSN: 0004212184 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020503871A (ja) * | 2017-01-09 | 2020-02-06 | レプリミュン リミテッド | 改変ウイルス |
JP2022539779A (ja) * | 2019-07-04 | 2022-09-13 | イムヴィラ・カンパニー・リミテッド | 腫瘍を治療するための医薬組成物、キット及び方法 |
JP7362156B2 (ja) | 2019-07-04 | 2023-10-17 | イムヴィラ・カンパニー・リミテッド | 腫瘍を治療するための医薬組成物、キット及び方法 |
JP2022544327A (ja) * | 2019-08-16 | 2022-10-17 | イムヴィラ・カンパニー・リミテッド | 全身投与のための腫瘍溶解性単純ヘルペスウイルスを含む医薬組成物 |
JP7388777B2 (ja) | 2019-08-16 | 2023-11-29 | イムヴィラ・カンパニー・リミテッド | 全身投与のための腫瘍溶解性単純ヘルペスウイルスを含む医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2020204209A1 (en) | 2020-07-16 |
JP6802275B2 (ja) | 2020-12-16 |
EP3380621A4 (en) | 2019-05-08 |
CN108350468B (zh) | 2020-10-30 |
AU2016403583A1 (en) | 2018-06-07 |
CN112575036A (zh) | 2021-03-30 |
WO2017181420A1 (en) | 2017-10-26 |
IL262385B2 (en) | 2024-01-01 |
IL262385B1 (en) | 2023-09-01 |
RU2018136481A3 (ja) | 2020-05-22 |
HK1251017A1 (zh) | 2019-01-18 |
AU2016403583B2 (en) | 2020-05-28 |
US20190083555A1 (en) | 2019-03-21 |
US10821140B2 (en) | 2020-11-03 |
RU2018136481A (ru) | 2020-05-22 |
KR102211838B1 (ko) | 2021-02-03 |
RU2751236C2 (ru) | 2021-07-12 |
KR20180096778A (ko) | 2018-08-29 |
CA3021588A1 (en) | 2017-10-26 |
US11439679B2 (en) | 2022-09-13 |
KR20210013366A (ko) | 2021-02-03 |
US20200405792A1 (en) | 2020-12-31 |
EP3380621A1 (en) | 2018-10-03 |
NZ746916A (en) | 2020-08-28 |
CN108350468A (zh) | 2018-07-31 |
IL262385A (en) | 2018-11-29 |
AU2020204209B2 (en) | 2022-08-04 |
KR102323872B1 (ko) | 2021-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6802275B2 (ja) | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 | |
US20220135980A1 (en) | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | |
Haines et al. | ONCR-177, an oncolytic HSV-1 designed to potently activate systemic antitumor immunity | |
US20200270613A1 (en) | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment | |
TWI666321B (zh) | 用於癌症治療的溶瘤性單純皰疹病毒(oHSV)專性載體及其建構體的建構 | |
JP7235334B2 (ja) | 癌の治療に用いる腫瘍溶解性単純ヘルペスウイルス(oHSV)偏性ベクター及びその構築体の構築 | |
CN114375331B (zh) | 用于脑肿瘤治疗的溶瘤性i型单纯疱疹病毒 | |
US20220064672A1 (en) | Engineered oncolytic viruses expressing pd-l1 inhibitors and uses thereof | |
TW202223085A (zh) | 用於腦腫瘤治療的溶瘤性i型單純皰疹病毒 | |
Shen | IL-12 CAR T cell Immunotherapy for Heterogeneous Brain Tumors | |
JP2023539382A (ja) | 改変b細胞及びそれらの使用方法 | |
Rakic | Oncolytic Vesicular Stomatitis Virus and Sunitinib Combination Therapy for Treating Neuroblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180831 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180831 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190709 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200514 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201027 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6802275 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |